Other reporting points in the same direction. 9to5Mac described Claude Opus 4.7 as the latest generally available version of Anthropic’s main AI model, with a focus on advanced software development, while noting that Mythos is not generally available . The Verge, citing the Opus 4.7 system card, reported that Opus 4.7 did not advance Anthropic’s capability frontier because Claude Mythos Preview scored higher on the relevant evaluations . VentureBeat reported that Anthropic publicly released Opus 4.7 while keeping the more powerful Mythos limited to a small number of external enterprise partners for cybersecurity testing and vulnerability patching .

That supports a narrow conclusion: Claude Opus 4.7’s release, API availability and product positioning are easier to verify than GPT-5.5 Spud’s, based on the sources here . It does not prove that Claude Opus 4.7 is more reliable for checking medical literature, finding legal authorities or analysing investment evidence.

GPT-5.5 Spud: not proven worse, just not auditable yet

The available information on GPT-5.5 Spud is much thinner. Tokenmix’s article focuses on release-date predictions, Polymarket odds and a claim that pretraining had finished . Other visible material comes from X trending pages, Substack, Reddit and YouTube discussions or leak-style posts .

Those sources show that people are discussing Spud. They do not establish how the model performs in high-risk research. In the sources available here, there is no OpenAI release document, system card, formal model description or reproducible third-party comparison against Claude Opus 4.7 on medical, legal or investment tasks.

So GPT-5.5 Spud is not shown to be worse in this comparison. The more precise finding is that there is not enough public, auditable evidence yet.

What the evidence can and cannot support

Why “Claude is better documented” is not the same as “Claude is safer”

Claude Opus 4.7 has the stronger public paper trail. That matters: an official product page and several independent reports make its existence, API access and positioning easier to check .

But documentation of a model’s release is not the same as proof that its research output is dependable. For medical, legal and investment work, the missing evidence is more specific:

• Do the citations exist?
• Do the sources support the exact claims being made?
• Does the model confuse commentary with primary evidence?
• Does it surface contrary evidence, or only the convenient side?
• Does it clearly say when the record is incomplete?
• Does it avoid making decisions for users in high-risk personalised situations?

Without that kind of head-to-head testing, saying Claude Opus 4.7 is more trustworthy would go beyond the evidence. Saying GPT-5.5 Spud is more trustworthy would also go beyond the evidence.

If you must use either model, test it like a research assistant

Before using any model in high-risk research, treat it as a draft assistant, not as an authority. A practical evaluation should include:

1. Build the same test set for both models. Include medical, legal and investment questions with known answers, grey areas and conflicting sources.
2. Require citation for every key claim. Each important sentence should point to a source a human can open and inspect.
3. Check source alignment. Track missing sources, real sources that do not support the claim, over-reading, and omitted counter-evidence.
4. Test conservative behaviour. Include prompts that should trigger refusal or caution, such as personalised treatment, litigation strategy or individual stock recommendations.
5. Use expert review. Clinicians or researchers should review medical answers; qualified professionals in the relevant jurisdiction should review legal answers; financially literate reviewers should check investment analysis.
6. Control the comparison. Use the same prompts, documents, tool access and time limits so that a tool advantage is not mistaken for a model advantage.

Bottom line

Claude Opus 4.7 currently has the more traceable product story: official API information and multiple reports document its release, availability and positioning relative to Claude Mythos Preview . GPT-5.5 Spud, in the available sources, remains mostly a subject of predictions, social discussion and leak-style claims .

That means Claude Opus 4.7 is easier to verify as a product. It does not mean it has been proven better for high-risk medical, legal or investment research. A real answer requires formal, reproducible, task-level evaluations of evidence chains, citation accuracy, uncertainty handling and refusal behaviour.

Other reporting points in the same direction. 9to5Mac described Claude Opus 4.7 as the latest generally available version of Anthropic’s main AI model, with a focus on advanced software development, while noting that Mythos is not generally available . The Verge, citing the Opus 4.7 system card, reported that Opus 4.7 did not advance Anthropic’s capability frontier because Claude Mythos Preview scored higher on the relevant evaluations . VentureBeat reported that Anthropic publicly released Opus 4.7 while keeping the more powerful Mythos limited to a small number of external enterprise partners for cybersecurity testing and vulnerability patching .

That supports a narrow conclusion: Claude Opus 4.7’s release, API availability and product positioning are easier to verify than GPT-5.5 Spud’s, based on the sources here . It does not prove that Claude Opus 4.7 is more reliable for checking medical literature, finding legal authorities or analysing investment evidence.

GPT-5.5 Spud: not proven worse, just not auditable yet

The available information on GPT-5.5 Spud is much thinner. Tokenmix’s article focuses on release-date predictions, Polymarket odds and a claim that pretraining had finished . Other visible material comes from X trending pages, Substack, Reddit and YouTube discussions or leak-style posts .

Those sources show that people are discussing Spud. They do not establish how the model performs in high-risk research. In the sources available here, there is no OpenAI release document, system card, formal model description or reproducible third-party comparison against Claude Opus 4.7 on medical, legal or investment tasks.

So GPT-5.5 Spud is not shown to be worse in this comparison. The more precise finding is that there is not enough public, auditable evidence yet.

What the evidence can and cannot support

Why “Claude is better documented” is not the same as “Claude is safer”

Claude Opus 4.7 has the stronger public paper trail. That matters: an official product page and several independent reports make its existence, API access and positioning easier to check .

But documentation of a model’s release is not the same as proof that its research output is dependable. For medical, legal and investment work, the missing evidence is more specific:

• Do the citations exist?
• Do the sources support the exact claims being made?
• Does the model confuse commentary with primary evidence?
• Does it surface contrary evidence, or only the convenient side?
• Does it clearly say when the record is incomplete?
• Does it avoid making decisions for users in high-risk personalised situations?

Without that kind of head-to-head testing, saying Claude Opus 4.7 is more trustworthy would go beyond the evidence. Saying GPT-5.5 Spud is more trustworthy would also go beyond the evidence.

If you must use either model, test it like a research assistant

Before using any model in high-risk research, treat it as a draft assistant, not as an authority. A practical evaluation should include:

1. Build the same test set for both models. Include medical, legal and investment questions with known answers, grey areas and conflicting sources.
2. Require citation for every key claim. Each important sentence should point to a source a human can open and inspect.
3. Check source alignment. Track missing sources, real sources that do not support the claim, over-reading, and omitted counter-evidence.
4. Test conservative behaviour. Include prompts that should trigger refusal or caution, such as personalised treatment, litigation strategy or individual stock recommendations.
5. Use expert review. Clinicians or researchers should review medical answers; qualified professionals in the relevant jurisdiction should review legal answers; financially literate reviewers should check investment analysis.
6. Control the comparison. Use the same prompts, documents, tool access and time limits so that a tool advantage is not mistaken for a model advantage.

Bottom line

Claude Opus 4.7 currently has the more traceable product story: official API information and multiple reports document its release, availability and positioning relative to Claude Mythos Preview . GPT-5.5 Spud, in the available sources, remains mostly a subject of predictions, social discussion and leak-style claims .

That means Claude Opus 4.7 is easier to verify as a product. It does not mean it has been proven better for high-risk medical, legal or investment research. A real answer requires formal, reproducible, task-level evaluations of evidence chains, citation accuracy, uncertainty handling and refusal behaviour.